key: cord-0829562-es3j142p
authors: Cappellano, Giuseppe; Abreu, Hugo; Raineri, Davide; Scotti, Lorenza; Castello, Luigi; Vaschetto, Rosanna; Chiocchetti, Annalisa
title: High levels of circulating osteopontin in inflammatory lung disease regardless of Sars‐CoV‐2 infection
date: 2021-03-31
journal: EMBO Mol Med
DOI: 10.15252/emmm.202114124
sha: c98a0aa6b12dd964d12cde3089f28d48ed228973
doc_id: 829562
cord_uid: es3j142p

This study independently confirms increased levels of osteopontin in COVID‐19 patients but also suggests that osteopontin cannot be used as a biomarker of SARS‐CoV‐2 infection, as elevated levels of circulating osteopontin are found in inflammatory lung disease regardless of SARS‐CoV‐2 infection.[Image: see text]

(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. Depending on transfer agreements, referee reports obtained elsewhere may or may not be included in this compilation. Referee reports are anonymous unless the Referee chooses to sign their reports.) ***** Reviewer's comments ***** Referee #1 (Remarks for Author):

In their correspondence "High levels of circulating osteopontin in inflammatory lung disease regardless of Sars-Cov-2 infection." the authors test osteopontin as a biomarker for SARS-CoV-2 infection. The rationale is based on a report by Gibellini et al. published in 2020 addressing monocyte alterations in SARS-CoV-2 and showing increased osteopontin levels in COVID-19 patients. While Gibellini et al. had compared COVID-19 patients to healthy controls, the authors of this manuscript test whether increased osteopontin is specific for SARS-CoV-2 infection as opposed to other causes of pneumonia, which indeed turned out not to be the case. Even though this might not necessarily be surprising, it is an interesting finding worth reporting. Not least does it demonstrate that findings made with respect to COVID-19 need to be put into context and it needs to be discriminated between what is more general infection-associated inflammation and what is SARS-CoV-2-specific. There are some points to be addressed: 1) As an introduction it is stated that "Gibellini et al. (2020) showed that the bioenergetic alteration of the monocyte compartment affects the pathogenic response to Sars-Cov-2 infection". As such effects on the pathogenic response were not explicitly shown by Gibellini et al. and they rather demonstrated alterations to the monocytic compartment in COVID-19, please revise this introductory statement to more precisely reflect the findings of Gibellini et al.

2) "OPN is a multifaceted molecule involved in the inflammatory response: it modulates leukocyte activation, migration and differentiation and induces cytokine secretion both in acute and chronic inflammation.". Please provide a reference for the effects of OPN.

3) As OPN is affected in a broad array of conditions, the authors might want to indicate their criteria defining healthy controls. 4) Regarding the cohort of Sars-Cov-2 negative patients if possible please indicate whether these were viral, bacterial, any other pneumonia patients or how these characteristics were distributed within the cohort. 5) Even though OPN is not a marker for SARS-CoV-2 infection, could the authors speculate on whether increased OPN might be associated with a certain form or severity of COVID-19. There is quite some heterogeneity in the OPN levels reported in SARS-CoV-2 positive patients. It would be interesting to learn whether e.g. explicitly high levels are associated with severe disease. This might make OPN suitable not as a biomarker for SARS-CoV-2 per se but e.g. for the course of the acute disease or the intensity of inflammation. Q2) "OPN is a multifaceted molecule involved in the inflammatory response: it modulates leukocyte activation, migration and differentiation and induces cytokine secretion both in acute and chronic inflammation.". Please provide a reference for the effects of OPN. R2. As suggested, by the reviewer, we added the missing reference (Clemente et al., 2016).

Q3) As OPN is affected in a broad array of conditions, the authors might want to indicate their criteria defining healthy controls. R3. We thank the reviewer for his/her valuable suggestion. We edited the text to clarify it. Q4) Regarding the cohort of Sars-Cov-2 negative patients if possible please indicate whether these were viral, bacterial, any other pneumonia patients or how these characteristics were distributed within the cohort. R4. We thank the reviewer for his/her comment. We added the following sentences: 'Diagnosis at hospital admission were respiratory failure related to acute or acute-on-chronic heart failure (n=17), sepsis (n=16 of which 25% due to community acquired pneumonia), intracranial bleeding (n=8), trauma (n=5) and others (n=10)''. Q5) Even though OPN is not a marker for SARS-CoV-2 infection, could the authors speculate on whether increased OPN might be associated with a certain form or severity of COVID-19. There is quite some heterogeneity in the OPN levels reported in SARS-CoV-2 positive patients. It would be interesting to learn whether e.g. explicitly high levels are associated with severe disease. This might make OPN suitable not as a biomarker for SARS-CoV-2 per se but e.g. for the course of the acute disease or the intensity of inflammation. R5. The reviewer is right; we added in the text the following sentences: "OPN deregulation may impact on COVID- 19 Do the data meet the assumptions of the tests (e.g., normal distribution)? Describe any methods used to assess it.

Is there an estimate of variation within each group of data?

This checklist is used to ensure good reporting standards and to improve the reproducibility of published results. These guidelines are consistent with the Principles and Guidelines for Reporting Preclinical Research issued by the NIH in 2014. Please follow the journal's authorship guidelines in preparing your manuscript. 

the assay(s) and method(s) used to carry out the reported observations and measurements an explicit mention of the biological and chemical entity(ies) that are being measured. an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner.

a statement of how many times the experiment shown was independently replicated in the laboratory.

Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.

In the pink boxes below, please ensure that the answers to the following questions are reported in the manuscript itself. Every question should be answered. If the question is not relevant to your research, please write NA (non applicable). We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects.

definitions of statistical methods and measures:

a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).

Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship guidelines on Data Presentation.

Please fill out these boxes ê (Do not worry if you cannot see all your text once you press return) a specification of the experimental system investigated (eg cell line, species name). 

F-Data Accessibility

The study was approved by the local ethics committee (CE67/20).

Informed consent was obtained from all human subjects or their legal representatives involved in the study and approved by the local ethics committee (CE67/20 

To show that antibodies were profiled for use in the system under study (assay and species), provide a citation, catalog number and/or clone number, supplementary information or reference to an antibody validation profile. e.g., Antibodypedia (see link list at top right)

Identify the source of cell lines and report if they were recently authenticated (e.g., by STR profiling) and tested for mycoplasma contamination

Report species, strain, gender, age of animals and genetic modification status where applicable. Please detail housing and husbandry conditions and the source of animals

For experiments involving live vertebrates, include a statement of compliance with ethical regulations and identify the committee(s) approving the experiments

), e1000412, 2010) to ensure that other relevant aspects of animal studies are adequately reported. See author guidelines, under 'Reporting Guidelines'. See also: NIH (see link list at top right) and MRC (see link list at top right) recommendations

For publication of patient photos, include a statement confirming that consent to publish was obtained. 14. Report any restrictions on the availability (and/or on the use) of human data or samples

Report the clinical trial registration number (at ClinicalTrials.gov or equivalent)

For phase II and III randomized controlled trials, please refer to the CONSORT flow diagram (see link list at top right) and submit the CONSORT checklist (see link list at top right) with your submission. See author guidelines, under 'Reporting Guidelines

Provide a "Data Availability" section at the end of the Materials & Methods, listing the accession codes for data generated in this study and deposited in a public database (e.g. RNA-Seq data: Gene Expression Omnibus GSE39462, Proteomics data: PRIDE PXD000208 etc

Data deposition in a public repository is mandatory for: a. Protein, DNA and RNA sequences

Deposition is strongly recommended for any datasets that are central and integral to the study; please consider the journal's data policy. If no structured public repository exists for a given data type, we encourage the provision of datasets in the manuscript as a Supplementary Document (see author guidelines under 'Expanded View' or in unstructured repositories such as Dryad (see link list at top right) or Figshare

Access to human clinical and genomic datasets should be provided with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public accesscontrolled repositories such as dbGAP (see link list at top right) or EGA

Computational models that are central and integral to a study should be shared without restrictions and provided in a machine-readable form. The relevant accession numbers or links should be provided. When possible, standardized format (SBML, CellML) should be used instead of scripts (e.g. MATLAB)

We are pleased to inform you that your manuscript is accept ed for publicat ion and is now being sent to our publisher to be included in the next available issue of EMBO Molecular Medicine.